1. Home
  2. MIRM vs CVCO Comparison

MIRM vs CVCO Comparison

Compare MIRM & CVCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIRM
  • CVCO
  • Stock Information
  • Founded
  • MIRM 2018
  • CVCO 1965
  • Country
  • MIRM United States
  • CVCO United States
  • Employees
  • MIRM 349
  • CVCO N/A
  • Industry
  • MIRM Biotechnology: Pharmaceutical Preparations
  • CVCO Homebuilding
  • Sector
  • MIRM Health Care
  • CVCO Consumer Discretionary
  • Exchange
  • MIRM Nasdaq
  • CVCO Nasdaq
  • Market Cap
  • MIRM 3.7B
  • CVCO 3.6B
  • IPO Year
  • MIRM 2019
  • CVCO N/A
  • Fundamental
  • Price
  • MIRM $72.85
  • CVCO $522.74
  • Analyst Decision
  • MIRM Strong Buy
  • CVCO Buy
  • Analyst Count
  • MIRM 11
  • CVCO 2
  • Target Price
  • MIRM $76.09
  • CVCO $522.50
  • AVG Volume (30 Days)
  • MIRM 712.9K
  • CVCO 206.0K
  • Earning Date
  • MIRM 11-11-2025
  • CVCO 10-30-2025
  • Dividend Yield
  • MIRM N/A
  • CVCO N/A
  • EPS Growth
  • MIRM N/A
  • CVCO 34.06
  • EPS
  • MIRM N/A
  • CVCO 23.02
  • Revenue
  • MIRM $429,161,000.00
  • CVCO $2,094,716,000.00
  • Revenue This Year
  • MIRM $53.14
  • CVCO $10.79
  • Revenue Next Year
  • MIRM $19.83
  • CVCO $5.69
  • P/E Ratio
  • MIRM N/A
  • CVCO $22.70
  • Revenue Growth
  • MIRM 62.33
  • CVCO 16.60
  • 52 Week Low
  • MIRM $36.88
  • CVCO $393.53
  • 52 Week High
  • MIRM $78.10
  • CVCO $600.00
  • Technical
  • Relative Strength Index (RSI)
  • MIRM 56.46
  • CVCO 40.46
  • Support Level
  • MIRM $70.49
  • CVCO $490.90
  • Resistance Level
  • MIRM $74.96
  • CVCO $596.39
  • Average True Range (ATR)
  • MIRM 1.82
  • CVCO 20.05
  • MACD
  • MIRM -0.72
  • CVCO -12.38
  • Stochastic Oscillator
  • MIRM 51.03
  • CVCO 11.09

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About CVCO Cavco Industries Inc. When Issued

Cavco Industries Inc designs and produces factory-built homes under the Cavco Homes, Fleetwood Homes, and Palm Harbor Homes brands. It also produces modular homes, park model homes, and vacation cabins, as well as commercial structures, among others. The company operates principally in two segments: Factory-built housing, which includes wholesale and retail systems-built housing operations, and the Financial services segment, which includes manufactured housing consumer finance and insurance. Cavco receives a majority of its revenue from the Factory-built housing segment.

Share on Social Networks: